Author: Paul Scherrer Institute
Source: Press Release
Publication Date: 08.12.2025
Reading Time: approx. 4 minutes
Executive Summary
The Insel Gruppe and the Paul Scherrer Institute (PSI) are strengthening their collaboration to optimize eye tumor treatment through a novel, integrated patient pathway. The goal is a highly precise, rapid, and coordinated proton therapy that offers patients maximum treatment safety and tissue preservation.
Critical Guiding Questions
- Freedom: Does the cooperation improve treatment options for patients?
- Responsibility: How is patient safety ensured?
- Transparency: Are all treatment steps traceable?
- Innovation: What technological advances does proton therapy enable?
Scenario Analysis
| Time Horizon | Expected Development |
|---|---|
| Short-term (1 year) | Establishment of the new treatment pathway |
| Medium-term (5 years) | National expansion of proton therapy |
| Long-term (10-20 years) | International role model for Swiss cancer medicine |
Main Summary
Core Topic
The cooperation between PSI and Insel Gruppe creates a standardized treatment process for eye tumor patients, especially for uveal melanomas.
Key Facts
- Proton therapy enables sub-millimeter precise tumor irradiation
- Maximum preservation of healthy eye tissue
- Accelerated access to specialized treatment processes
Stakeholders
- Winners: Eye tumor patients
- Participants: PSI, Insel Gruppe, Oncologists
- Beneficiaries: Swiss healthcare system
Opportunities & Risks
| Opportunities | Risks |
|---|---|
| Preservation of vision | Limited therapy availability |
| More precise treatment | High treatment costs |
| Faster therapy access | Technological complexity |
Action Relevance
Decision-makers should closely monitor the development of proton therapy and its financing.
Source Directory
Primary Source:
PSI Press Release – https://www.psi.ch
Supplementary Sources:
This text was created with the support of an AI model.
Editorial responsibility: clarus.news | Fact-check: 2025-12-08